189 related articles for article (PubMed ID: 30066796)
1. Levetiracetam and lamotrigine effects as mono- and polytherapy on bone mineral density in epileptic patients.
El-Haggar SM; Mostafa TM; Allah HMS; Akef GH
Arq Neuropsiquiatr; 2018 Jul; 76(7):452-458. PubMed ID: 30066796
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density in adult patients treated with various antiepileptic drugs.
Beniczky SA; Viken J; Jensen LT; Andersen NB
Seizure; 2012 Jul; 21(6):471-2. PubMed ID: 22541979
[TBL] [Abstract][Full Text] [Related]
3. Reproductive endocrine health in pubertal females with epilepsy on antiepileptic drugs: time to screen?
Rauchenzauner M; Roscia S; Prieschl M; Wildt L; Haberlandt E; Baumann M; Rostasy K; Agostinelli S; Pizzolorusso A; Luef G; Verrotti A
Neuropediatrics; 2014 Aug; 45(4):226-33. PubMed ID: 24407471
[TBL] [Abstract][Full Text] [Related]
4. Effects of valproate, lamotrigine, and levetiracetam monotherapy on bone health in newly diagnosed adult patients with epilepsy.
Guo Y; Lin Z; Huang Y; Yu L
Epilepsy Behav; 2020 Dec; 113():107489. PubMed ID: 33220583
[TBL] [Abstract][Full Text] [Related]
5. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy.
Guo CY; Ronen GM; Atkinson SA
Epilepsia; 2001 Sep; 42(9):1141-7. PubMed ID: 11580761
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of anti-epileptic drugs-an internet study.
Wieshmann UC; Baker G
Acta Neurol Scand; 2017 May; 135(5):533-539. PubMed ID: 27757951
[TBL] [Abstract][Full Text] [Related]
7. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy.
Pack AM; Morrell MJ; Randall A; McMahon DJ; Shane E
Neurology; 2008 Apr; 70(18):1586-93. PubMed ID: 18443309
[TBL] [Abstract][Full Text] [Related]
8. Monotherapy with Levetiracetam Versus Older AEDs: A Randomized Comparative Trial of Effects on Bone Health.
Hakami T; O'Brien TJ; Petty SJ; Sakellarides M; Christie J; Kantor S; Todaro M; Gorelik A; Seibel MJ; Yerra R; Wark JD
Calcif Tissue Int; 2016 Jun; 98(6):556-65. PubMed ID: 26842957
[TBL] [Abstract][Full Text] [Related]
9. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs).
Stepanova D; Beran RG
Seizure; 2014 May; 23(5):371-6. PubMed ID: 24630809
[TBL] [Abstract][Full Text] [Related]
10. Haematological side effects of antiepileptic drug treatment in patients with epilepsy.
Bachmann T; Bertheussen KH; Svalheim S; Rauchenzauner M; Luef G; Gjerstad L; Taubøll E
Acta Neurol Scand Suppl; 2011; (191):23-7. PubMed ID: 21711253
[TBL] [Abstract][Full Text] [Related]
11. The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study.
Rosenow F; Schade-Brittinger C; Burchardi N; Bauer S; Klein KM; Weber Y; Lerche H; Evers S; Kovac S; Hallmeyer-Elgner S; Winkler G; Springub J; Niedhammer M; Roth E; Eisensehr I; Berrouschot J; Arnold S; Schröder M; Beige A; Oertel WH; Strzelczyk A; Haag A; Reif PS; Hamer HM;
J Neurol Neurosurg Psychiatry; 2012 Nov; 83(11):1093-8. PubMed ID: 22595362
[TBL] [Abstract][Full Text] [Related]
12. Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy.
Koo DL; Joo EY; Kim D; Hong SB
Epilepsy Res; 2013 Mar; 104(1-2):134-9. PubMed ID: 23032070
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study.
Tomson T; Battino D; Bonizzoni E; Craig J; Lindhout D; Perucca E; Sabers A; Thomas SV; Vajda F;
Neurology; 2015 Sep; 85(10):866-72. PubMed ID: 26085607
[TBL] [Abstract][Full Text] [Related]
14. Preliminary evidence for gender effects of levetiracetam monotherapy duration on bone health of patients with epilepsy.
Artemiadis AK; Lambrinoudaki I; Voskou P; Tsivgoulis G; Safouris A; Bougea A; Giannopoulos S; Gatzonis S; Triantafyllou N
Epilepsy Behav; 2016 Feb; 55():84-6. PubMed ID: 26773675
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine.
Svalheim S; Luef G; Rauchenzauner M; Mørkrid L; Gjerstad L; Taubøll E
Acta Neurol Scand Suppl; 2010; (190):30-3. PubMed ID: 20586732
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate.
Chowdhury A; Brodie MJ
Epilepsy Res; 2016 Jan; 119():62-6. PubMed ID: 26675554
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral density with lamotrigine monotherapy for epilepsy.
Sheth RD; Hermann BP
Pediatr Neurol; 2007 Oct; 37(4):250-4. PubMed ID: 17903668
[TBL] [Abstract][Full Text] [Related]
18. Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy.
Huber-Mollema Y; Oort FJ; Lindhout D; Rodenburg R
Epilepsia; 2019 Jun; 60(6):1069-1082. PubMed ID: 31166022
[TBL] [Abstract][Full Text] [Related]
19. The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy.
Takeuchi T; Natsume J; Kidokoro H; Ishihara N; Yamamoto H; Azuma Y; Ito Y; Kurahashi N; Tsuji T; Suzuki M; Itomi K; Yamada K; Kurahashi H; Abe S; Okumura A; Maruyama K; Negoro T; Watanabe K; Kojima S
Brain Dev; 2016 Sep; 38(8):723-30. PubMed ID: 27033151
[TBL] [Abstract][Full Text] [Related]
20. Self-reported symptoms in patients on antiepileptic drugs in monotherapy.
Wieshmann UC; Tan GM; Baker G
Acta Neurol Scand; 2011 Nov; 124(5):355-8. PubMed ID: 21973277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
